Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.
Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C.
Azoitei N, et al. Among authors: ball cr.
J Exp Med. 2012 Apr 9;209(4):697-711. doi: 10.1084/jem.20111910. Epub 2012 Mar 26.
J Exp Med. 2012.
PMID: 22451720
Free PMC article.